Abstract
Chagas disease by Trypanosoma cruzi (T. cruzi) infection is a leading cause of myocarditis worldwide. Chagas cardiomyopathy is presented with a wide variety of conduction abnormalities including arrhythmias, first- and second-degree atrioventricular blockade, left ventricular systolic dysfunction and some cases heart failure leading to the death. Currently, there are no effective treatments available against advanced Chagas disease. With the advance in the development of novel therapies, it is important to utilize an animal model that can effectively replicate the diverse stages of Chagas disease, including chronic asymptomatic and symptomatic infection, that are akin to those observed in humans. Therefore, to characterize the cardiac alterations during the evolution of the infection, we evaluated the progression of cardiomyopathy caused by T. cruzi H1 infection in both BALB/c and ICR mouse models by performing electrocardiogram (ECG) studies in unanesthetized mice every month until 210 days post-infection (dpi). In the late chronic phase of infection, we also performed echocardiogram (ECHO) studies to further assess cardiac function. In conclusion, we demonstrated that ICR mice were more susceptible to cardiac alterations compared to BALB/c mice and both mouse strains are suitable experimental models to study chronic T. cruzi infection and novel treatments.
Funder
Fundación Carlos Slim
Consejo Nacional de Ciencia y Tecnología, México
CONACYT
Publisher
Public Library of Science (PLoS)
Reference42 articles.
1. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015.;Global Burden of Disease 2015 Disease and Injury Incidence and Prevalence Collaborators;Lancet,2016
2. Chemokines, inflammation and Trypanosoma cruzi infection;MM Teixeira;Trends Parasitol,2002
3. Diagnosis and management of Chagas disease and cardiomyopathy.;AL Ribeiro;Nat Rev Cardiol,2012
4. Chronic Chagas cardiomyopathy: a review of the main pathogenic mechanisms and the efficacy of aetiological treatment following the BENznidazole Evaluation for Interrupting Trypanosomiasis (BENEFIT) trial.;A Rassi;Mem Inst Oswaldo Cruz,2017
5. Value of echocardiography for diagnosis and prognosis of chronic Chagas disease cardiomyopathy without heart failure;RJ Viotti;Heart,2004